Journal
SUPPORTIVE CARE IN CANCER
Volume 30, Issue 9, Pages 7205-7218Publisher
SPRINGER
DOI: 10.1007/s00520-022-07068-5
Keywords
Cancer; Chemotherapy; Radiation therapy; Mucositis; Stomatitis; Prophylaxis
Ask authors/readers for more resources
Anti-inflammatory mouthwashes are a potentially effective means to prevent or reduce mucositis associated with cancer therapy, reducing the incidence of symptomatic mucositis and dose-limiting mucositis. Limited adverse effects and high adherence indicate the safety and feasibility of using these mouthwashes. They should be considered for supportive care in individuals at risk for mucositis and further evaluated for efficacy across various chemotherapy agents, adverse effects, and impacts on symptoms, pain, and quality of life.
Purpose Mucositis is severely painful and often reported as one of the most distressing adverse effects of cancer therapy; it is a significant threat to quality of life as well as life itself. Anti-inflammatory agents may modulate physiologic mechanisms that perpetuate mucositis and be useful in prevention efforts. Because systemic anti-inflammatory agents are not appropriate for many patients, locally acting agents (mouthwashes) may be more feasible for use. This review and meta-analysis evaluates the role that anti-inflammatory mouthwashes have in preventing or reducing oral mucositis associated with chemotherapy and radiation therapy. Methods A systematic literature review was conducted to identify studies evaluating the efficacy of anti-inflammatory mouthwashes to prevent therapy-associated mucositis. Meta-analysis was conducted to determine efficacy in preventing any mucositis and dose-limiting mucositis. Results Eight peer-reviewed publications were identified; corticosteroid and nonsteroidal anti-inflammatory mouthwashes are effective in reducing overall incidence of mucositis and are associated with lower severity of mucositis. Meta-analysis reveals significant reduction in symptomatic mucositis incidence (OR 6.00, 95% CI 4.39-8.20, p < 0.0001) and reduction of dose-limiting mucositis (OR 2.12, 95% CI 1.07-4.28, p = 0.032). Conclusion Mouthwashes containing anti-inflammatory agents are a potential effective means to prevent or reduce mucositis associated with cancer therapy. There are limited adverse effects from these agents, and adherence is high, indicating safety and feasibility of use. Anti-inflammatory mouthwashes should be considered for supportive care in persons at risk for mucositis and must be further evaluated to investigate efficacy across multiple chemotherapy agents, adverse effects, and impacts on symptoms, pain, and quality of life.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available